Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3793_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
09.09.2026
Размер:
18 Мб
Скачать
138.e4 PART III Coronary Artery Disease
https://t.me/medicina_free
90. Metoprolol in acute myocardial infarction. Mortality. The MIAMI Trial Research Group. Am J Cardiol. 1985;56(14):15G–22G.
91. Group TS. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med. 1989;320(10):618–627.
92. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–1390.
93. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45(4):525–530.
94. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1622–1632.
95. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339(8):489–497.
96. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–371.
97. Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318(7200):1730–1737.
98. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001;37(7):1950–1956.
99. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137(9):715–725.
100. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol. 1997;29(2):229–236.
101. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1999;33(4):916–923.
102. Spargias KS, Hall AS, Greenwood DC, Ball SG. beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. Heart. 1999;81(1):25–32.
103. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med. 1991;151(9):1769–1776.
104. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Arch Intern Med. 2000;160(7):947–952.
105. Jugdutt BI. Nitrates in myocardial infarction. Cardiovasc Drugs Ther. 1994;8(4):635–646.
106. Diodati J, Theroux P, Latour JG, et al. Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. Am J Cardiol. 1990;66(7):683–688.
107. Gorman MW, Sparks HV Jr. Nitroglycerin causes vasodilatation within ischaemic myocardium. Cardiovasc Res. 1980;14(9):515–521.
108. Jugdutt BI. Myocardial salvage by intravenous nitroglycerin in conscious dogs: loss of beneficial effect with marked nitroglycerin-induced hypotension. Circulation. 1983;68(3):673–684.
109. Jugdutt BI, Warnica JW. Tolerance with low dose intravenous nitroglycerin therapy in acute myocardial infarction. Am J Cardiol. 1989;64(10):581–587.
110. Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet. 1988;1(8594):1088–1092.
111. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet. 1994;343(8906):1115–1122.
112. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345(8951):669–685.
113. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/ American Heart Association. J Am Coll Cardiol. 1999;33(1):273–282.
114. Timmermans PB, Carini DJ, Chiu AT, et al. Angiotensin II receptor antagonists. From discovery to antihypertensive drugs. Hypertension. 1991;18(5 suppl):III136–III142.
115. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–2610.
116. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–677.
117. St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994;89(1):68–75.
118. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988;319(2):80–86.
119. Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation. 1993;88(5 Pt 1):2277–2283.
CHAPTER 12 Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction 138.e5
https://t.me/medicina_free
120. Oosterga M, Voors AA, de Kam PJ, et al. Plasma angiotensin­converting enzyme activity and left ventricular dilation after myocardial infarction. Circulation. 1997;95(12):2607–2609.
121. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327(10):678–684.
122. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342(8875):821–828.
123. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332(2):80–85.
124. Investigators S, Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.
125. Investigators S, Yusuf S, Pitt B, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685–691.
126. Group CTS. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–1435.
127. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333(25):1670–1676.
128. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet. 1995;345(8951):686–687.
129. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998;97(22):2202–2212.
130. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation. 1995;92(10):3132–3137.
131. Dickstein K, Kjekshus J, Group OSCotOS. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360(9335):752–760.
132. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–1906.
133. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717.
134. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction
after myocardial infarction. N Engl J Med. 2003;348(14): 1309–1321.
135. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352(25):2581–2588.
136. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481–2488.
137. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46(3):425–431.
138. Pitt B, Gheorghiade M, Zannad F, et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30percent. Eur J Heart Fail. 2006;8(3):295–301.
139. Kidney Disease Outcomes Quality I. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 suppl
1):S1–S290.
140. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585–592.
141. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234–242.
142. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165(14):1637–1642.
143. Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest. 2004;126(2):400–404.
144. Abdi R, Dong VM, Lee CJ, Ntoso KA. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy. 2002;22(9):1173–1175.
145. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med. 2004;164(8):910–913.
146. Dykewicz MS. Cough and angioedema from angiotensin­converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol. 2004;4(4):267–270.
147. Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation. 1984;69(4):740–747.
148. Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med. 1993;153(3): 345–353.
149. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol. 1990;66(10):779–785.
150. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med. 1986;315(7):423–429.
138.e6 PART III Coronary Artery Disease
https://t.me/medicina_free
151. Held PH, Yusuf S. Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J. 1993;14(supplF):18–25.
152. Investigators G. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673–682.
153. Alexander JH, Granger CB, Sadowski Z, et al. Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. Am Heart J. 1999;137(5):799–805.
154. MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA. 1988;260(13):1910–1916.
155. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781–788.
156. Hjalmarson A, Herlitz J, Holmberg S, et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation. 1983;67(6 Pt 2):I26–I32.
157. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(18 suppl 2):S444–S464.
158. Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005;149(6):1043–1049.
159. Hobl EL, Stimpfl T, Ebner J, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double­blind, placebo-controlled trial. J Am Coll Cardiol. 2014;63(7):630–635.
160. Silvain J, Storey RF, Cayla G, et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE­ATLANTIC study. Thromb Haemost. 2016;116(2):369–378.
161. Thomas MR, Morton AC, Hossain R, et al. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost. 2016;116(1):96–102.
162. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906–2913.
163. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634–1642.
164. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–1080.
165. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high­intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556–1565.
166. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389.
167. Long-Term Intervention with Pravastatin in Ischaemic Disease Study G. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349–1357.
168. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001–1009.
169. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504.
170. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–1718.
171. Stenestrand U, Wallentin L. Swedish Register of Cardiac Intensive C. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285(4):430–436.
172. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357(9262):1063–1068.
173. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87(7):819–822.
174. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239.
175. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–2934.
176. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387–2397.
177. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713–1722.
178. Hirsh J. Heparin. N Engl J Med. 1991;324(22):1565–1574.
179. Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989;320(6):352–357.
180. Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparin­induced thrombocytopenia. J Am Coll Cardiol. 1998;31(7):1449–1459.
181. Gruel Y, Pouplard C, Nguyen P, et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol. 2003;121(5):786–792.
182. Napolitano LM, Warkentin TE, Almahameed A, Nasraway SA. Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management. Crit Care Med. 2006;34(12):2898–2911.
183. Mahaffey KW, Granger CB, Collins R, et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol. 1996;77(8):551–556.
CHAPTER 12 Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction 138.e7
https://t.me/medicina_free
184. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996;93(5):870–878.
185. Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol. 1993;22(4):1004–1009.
186. Yusuf S, Mehta SR, Xie C, et al. Effects of reviparin, a low­molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA. 2005;293(4):427–435.
187. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295(13):1519–1530.
188. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot­bound thrombin is protected from inhibition by heparin­antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86(2):385–391.
189. White H. Hirulog, Early Reperfusion or Occlusion -2 Trial I. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358(9296):1855–1863.
190. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218–2230.
191. Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014;384(9957):1849–1858.
192. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90(1):61–68.
193. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143(4):241–250.
194. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27(5):519–526.
195. Reeder GS, Lengyel M, Tajik AJ, et al. Mural thrombus in left ventricular aneurysm: incidence, role of angiography, and relation between anticoagulation and embolization. Mayo Clin Proc. 1981;56(2):77–81.
196. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699–708.
197. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.
198. Mega JL, Braunwald E, Murphy SA, et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial
(Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol. 2013;61(18):1853–1859.
199. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–1115.
200. Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375(25):2423–2434.
201. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. J Am Coll Cardiol. 1996;27(2):337–344.
202. Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation. 1997;95(12):2643–2651.
203. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349(9054):747–752.
204. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100(10):1056–1064.
205. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial–the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582–1587.
206. Cohn JN, Tognoni G, Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–
1675.
207. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759–766.
208. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting­enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767–771.
209. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left­ventricular systolic function intolerant to angiotensin­converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772–776.
210. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left­ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–781.
SECTION 2 Complications of Acute Myocardial Infarction
https://t.me/medicina_free
Postmyocardial Infarction Cardiogenic Shock
OUTLINE
Epidemiology, 139
Definition, 139 Etiology, 139 Incidence, 140
Pathogenesis, 140
Pathology, 140 Pathophysiology, 140
Clinical Presentation, 141
History and Physical Examination, 141 Electrocardiography and Laboratory
Testing, 142
Echocardiography, 142
Management, 142
General Measures, 142 Hemodynamic Monitoring, 142 Pharmacologic Support, 144 Mechanical Support, 145
Reperfusion Strategies, 147
Fibrinolytic Therapy, 147 Percutaneous Coronary Intervention, 148 Surgery, 149
New Approaches, 149 Prognosis, 149 Conclusion, 150
13
Eric R. Bates
Dramatic advances during the past several decades in diagnosing, monitoring, and treating patients with acute myocardial infarction (MI) have decreased hospital mortality rates by 50%. The organization of coronary care units in the 1960s to treat lethal arrhythmias1 and the development of fibrinolytic therapy in the 1980s to reduce infarct size Cardiogenic shock, not arrhythmia, is the most common cause of death in patients hospitalized with acute MI. Neither the incidence nor the mortality rate associated with cardiogenic shock has been reduced by modern cardiac intensive care unit interventions, including vasopressor and inotropic drug infusions, hemodynamic monitoring, and intraaortic balloon pump (IABP) counterpulsation (Table 13.1). has been demonstrated for patients who undergo successful reperfusion with percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). reviews the epidemiology, pathogenesis, clinical presentation, and current management of cardiogenic shock.
2–5
were the biggest breakthroughs.
6–12
However, a survival advantage
13–19
This chapter
EPIDEMIOLOGY
Definition
Circulatory shock is characterized by the inability of multiorgan blood flow and oxygen delivery to meet metabolic demands.
Cardiogenic shock is a type of circulatory shock resulting from severe impairment of ventricular pump function rather than from abnormalities of the vascular system or blood volume. It is important to separate the shock state, in which tissue perfusion is inadequate, from hypotension, in which tissue metabolic demands may be met by increasing cardiac output or decreasing systemic vascular resistance. The diagnosis of cardiogenic shock should include the following:
1. Systolic blood pressure less than 80 mm Hg without inotropic
or vasopressor support, or less than 90 mm Hg with inotropic or vasopressor support, for at least 30 minutes
2. Low cardiac output (<2.0 L/min per m2) not related to
hypovolemia (pulmonary artery wedge pressure <12 mm Hg), arrhythmia, hypoxemia, acidosis, or atrioventricular block
3. Tissue hypoperfusion manifested by oliguria (<30 mL/h),
peripheral vasoconstriction, or altered mental status
The failure to consistently define cardiogenic shock or to hemodynamically confirm the presence of an elevated pulmonary capillary wedge pressure and low cardiac index have previously confused clinicians and confounded the literature.
Etiology
The most common cause of cardiogenic shock is acute MI.20 Often, anterior MI due to acute thrombotic occlusion of the left
139
CHAPTER 13 Postmyocardial Infarction Cardiogenic Shock 139.e1
https://t.me/medicina_free
Key Words
Cardiogenic shock Myocardial infarction Percutaneous coronary intervention
140 PART III Coronary Artery Disease
https://t.me/medicina_free
TABLE 13.1 Historical Milestones in
Cardiogenic Shock
1934 Fishberg et al.6 described the shock state as a peripheral
complication of myocardial infarction.
1942 Stead and Ebert
dysfunction. 1954 1967 Killip and Kimball
1968 1972 1973 1976
1980 1980
1982 1988 1999
CABG, Coronary artery bypass graft surgery; IABP, intraaortic balloon pump; PTCA, percutaneous transluminal coronary angioplasty.
Griffith et al.8 used L-norepinephrine as pressor support.
care unit monitoring.
Kantrowitz et al.9 described the clinical use of the IABP. Dunkman et al.10 demonstrated successful treatment with CABG. Scheidt et al.11 showed no survival advantage with IABP. Forrester et al.12 defined hemodynamic subsets using the
pulmonary artery catheter.
DeWood et al.13 showed a survival advantage with early CABG. Mathey et al.14 demonstrated successful treatment with
fibrinolytic therapy.
Meyer et al.15 demonstrated successful treatment with PTCA. Lee et al.16 showed a survival advantage with PTCA. Hochman et al.
revascularization in the SHOCK trial.
7
attributed the shock state to extreme myocardial
1
showed no survival advantage with coronary
17–19
proved a survival advantage with
anterior descending artery results in extensive infarction. Alter­natively, a smaller MI in a patient with borderline left ventricular function may be responsible for insufficient cardiac output. Large areas of ischemic nonfunctioning but viable myocardium occasionally lead to shock in patients with MI. The delayed onset of shock may result from reocclusion of a previously patent infarct artery, infarct extension, or metabolic decompensation of noninfarct-zone regional wall motion. Occasionally, right ventricular MI from occlusion of a proximal large right coronary artery in a patient with inferior MI is the cause.
21
Mechanical complications unrelated to infarct size account for approximately 12% of cases. The papillary muscle of the mitral valve may infarct or rupture, causing acute, severe mitral regurgitation.22 Rupture of the interventricular septum causing ventricular septal defect23 or rupture of the left ventricular free wall producing pericardial tamponade24 also needs to be considered.
Other causes of cardiogenic shock are not emphasized in this discussion. These include end-stage cardiomyopathy, myocardial contusion, myocarditis, hypertrophic cardiomyopathy, valvular heart disease, pericardial disease, right ventricular infarction, and post-cardiopulmonary bypass.
Incidence
Before the recent emphasis on time to treatment and primary PCI, the incidence of cardiogenic shock had remained unchanged for over 25 years, with approximately 8% of patients with ST elevation myocardial infarction (STEMI) with non-STEMI
27,28
developing cardiogenic shock. The latter group is more likely to have circumflex artery occlusion, comorbid disease, and severe three-vessel disease or left main disease.28 Cardiogenic shock usually develops early after onset of symptoms, with approximately half of the patients developing shock within 6 hours and 72% within 24 hours.29 Others first develop a preshock
25,26
and 2.5% of patients
state manifested by systemic hypoperfusion without hypotension.30 These patients benefit from aggressive supportive therapy and revascularization; early intervention may abort the onset of cardiogenic shock.
PATHOGENESIS
Pathology
The early development of cardiogenic shock is usually caused by acute thrombosis of a coronary artery supplying a large myocardial distribution, with no collateral flow recruitment.31 Frequently, this is the left anterior descending artery, although shock may result from coronary thrombosis in other sites if previous MI has occurred. Multivessel disease is present in two­thirds of patients.
Autopsy studies have consistently shown that at least 40% of the myocardium is infarcted in patients who die of cardiogenic shock.33 Various ages of infarction reflect previous infarction, reinfarction, or infarct extension.
The infarct border zone in patients without hypotension is clearly demarcated. In patients succumbing to shock, however, it is irregular, with marginal extension. Focal areas of necrosis remote from the infarct zone are also present. These findings result from progressive cell death due to poor coronary perfusion, are reflected by prolonged release of cardiac enzymes, and contribute to hemodynamic deterioration.
Pathophysiology
Progressive hemodynamic deterioration resulting in cardiogenic shock results from a sequence of events (Fig. 13.1). A critical amount of ischemic or necrotic myocardium decreases contractile mass and cardiac output. When cardiac output is low enough that arterial blood pressure falls, coronary perfusion pressure decreases in the setting of an elevated left ventricular end-diastolic pressure. The resulting reduction in coronary perfusion pressure gradient from epicardium to endocardium exacerbates myocardial ischemia, further decreasing left ventricular function and cardiac output, perpetuating a vicious cycle. The speed with which this process develops is modified by the infarct zone, remote myocardial function, neurohumoral responses, and metabolic abnormalities.
The infarct zone can be enlarged by reocclusion of a previously patent infarct artery. Alternatively, infarct extension can result from side branch occlusion from coronary thrombus propagation or embolization or by thrombosis of a second stenosis stimulated by low coronary blood flow and hypercoagulability. Infarct expansion or aneurysm formation promotes left ventricular dilation, which increases wall stress and oxygen demand in the setting of decreased oxygen supply due to low cardiac output.
Preclinical and clinical studies importance of hypercontractility of remote myocardial segments in maintaining cardiac output in the setting of a large myocardial infarction. This compensatory mechanism is lost when multivessel disease is present and severe enough to produce ischemia in noninfarct segments.
A series of neurohumoral responses is activated in an attempt to restore cardiac output and vital organ perfusion. Decreased
32
34
35
have demonstrated the
CHAPTER 13 Postmyocardial Infarction Cardiogenic Shock 141
y congestion
https://t.me/medicina_free
Systemic
IL-6
IL-7
IL-8
IL-10
IF
G-CSF
MCP-1
MCP-1β
Fig. 13.1 Prognostically relevant components of cardiogenic shock complicating myocardial
infarction. In addition to severe systolic and diastolic cardiac dysfunction compromising macro­circulation and microcirculation, systemic inflammatory response syndrome and even sepsis may develop, finally resulting in multiorgan dysfunction syndrome.The proinflammatory and antiinflam­matory cytokines mentioned have prognostic significance, with either higher () or lower (↓) serum levels in nonsurvivors compared with survivors. G-CSF, Granulocyte colony-stimulating factor; IF, interferon; IL, interleukin; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; NO, nitric oxide; iNOS, inducible macrophage-type nitric oxide synthase. (Modified from Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107:2998–3002.)
Inflammatory
iNOS
NO
Peroxynitrite
inflammation
cytokines
Vasodilation
SVR
Systemic perfusion
perfusion pressure
Compensatory
vasoconstriction
Cardiac output Stroke volume
Hypotension
Coronary
Myocardial infarction
Myocardial dysfunction
Systolic
Pulmonar
Ischemia
Diastolic
LVEDP
Hypoxemia
Progressive
myocardial
dysfunction
Death
baroreceptor activity due to hypotension increases sympathetic outflow and reduces vagal tone. This increases heart rate, myo­cardial contractility, venous tone, and arterial vasoconstriction. Vasoconstriction is most pronounced in the skeletal, splanchnic, and cutaneous vascular beds to redistribute cardiac output to the coronary, renal, and cerebral circulations. An increase in the ratio of precapillary to postcapillary resistance decreases capillary hydrostatic pressure, facilitating movement of interstitial fluid into the vascular compartment. Increased catecholamine levels and decreased renal perfusion lead to renin release and angiotensin production. Elevated angiotensin levels stimulate peripheral vasoconstriction and aldosterone synthesis. Aldosterone increases sodium and water retention by the kidney, raising blood volume. Release of antidiuretic hormone from the posterior pituitary by baroreceptor stimulation also increases water retention. Local autoregulatory mechanisms that decrease arteriolar resistance and increase regional blood flow are stimulated by hypoxia, acidosis, and accumulation of vasoactive metabolites (e.g., adenosine).
Enhanced anaerobic metabolism, lactic acidosis, and depleted adenosine triphosphate (ATP) stores result when compensatory neurohumoral responses are overwhelmed, further depressing ventricular function. Arrhythmias may reduce cardiac output and increase myocardial ischemia as well. Loss of vascular endothelial integrity because of ischemia culminates in multiorgan failure. Pulmonary edema impairs gas exchange. Renal and hepatic dys­function results in fluid, electrolyte, and metabolic disturbances.
Gastrointestinal ischemia can lead to hemorrhage or entry of bacteria into the bloodstream, causing sepsis. Microvascular thrombosis due to capillary endothelial damage with fibrin deposition and catecholamine-induced platelet aggregation further impairs organ function.
A systemic inflammatory state with high plasma levels of
cytokines (e.g., tumor necrosis factor-α, interleukin-6) and inappropriate nitric oxide production may also depress myocardial function or impair catecholamine-induced vasoconstriction, respectively. All of these factors, in turn, lead to diminished coronary artery perfusion and thus trigger a vicious cycle of further myocardial ischemia and necrosis. This results in even lower blood pressure, lactic acidosis, multiorgan failure, and ultimately death.
36
CLINICAL PRESENTATION
History and Physical Examination
The diagnosis of acute MI must be confirmed. Noncardiac causes of shock need to be ruled out; these include aortic dissection, tension pneumothorax, massive pulmonary embolism, ruptured viscus, hemorrhage, and sepsis. Risk factors for developing cardiogenic shock include older age, anterior MI location, hypertension, diabetes mellitus, multivessel coronary artery disease, prior MI, prior congestive heart failure, STEMI, or left bundle branch block.
37,38
142 PART III Coronary Artery Disease
https://t.me/medicina_free
Patients usually appear ashen or cyanotic, with cold and clammy skin. They may be agitated, disoriented, or lethargic from cerebral hypoperfusion. The pulses are rapid and faint, the pulse pressure narrow, and arrhythmias are common. Jugular venous distention and pulmonary rales are usually present in left ventricular shock, but may be absent. Jugular venous disten­tion, Kussmaul sign (a paradoxic increase in jugular venous pressure during inspiration), and absent rales are found in right ventricular shock. Left ventricular dyskinesis may produce a precordial heave. A systolic thrill along the left sternal border is consistent with mitral regurgitation or ventricular septal defect. The heart sounds are distant. Third and fourth heart sounds or a summation gallop can be auscultated. The systolic murmur of mitral regurgitation is often present; ventricular septal defect also produces a systolic murmur. The absence of a murmur, however, does not exclude these complications. The extremities are usually vasoconstricted.
Electrocardiography and Laboratory Testing
A large anterior or anterolateral MI pattern is often present. Old anterior Q waves or new ST segment elevation in the right precordial leads consistent with right ventricular MI may be noted with acute inferior MI. Multiple lead ST segment depression without an injury current is another pattern that can occur with multivessel or left main disease. New left bundle branch block and third-degree atrioventricular conduction block are ominous findings. A relatively normal ECG should alert one to other causes of shock.
Troponin and creatine kinase levels are high, may peak late because of prolonged washout or ongoing necrosis, and can rise secondarily with infarct extension. Lactic acidosis, hypoxemia, and mixed venous oxygen desaturation are usually present.
Echocardiography
Echocardiography can be performed rapidly and offers valuable information on the extent of left ventricular dysfunction. A dilated, hypokinetic left ventricle suggests left ventricular shock, whereas a dilated right ventricle suggests right ventricular involvement. Normal ventricular function, low cardiac output, and mitral regurgitation are consistent with acute severe mitral regurgita­tion. Pericardial tamponade from hemorrhagic effusion or free wall rupture can quickly be detected. Doppler evaluation can easily confirm the presence of significant mitral regurgitation or ventricular septal rupture. Transesophageal echo is helpful in patients for whom image quality is inadequate or when a flail mitral leaflet is suspected but not seen on transthoracic echocardiography.
MANAGEMENT
General Measures
A number of supportive measures need to be instituted quickly (Fig. 13.2). If there is no clinical evidence for pulmonary edema, a fluid bolus should be given to exclude hypovolemia as a cause of hypotension. Patients with a history of inadequate fluid intake, diaphoresis, diarrhea, vomiting, or diuretic use may not have pump failure and will improve dramatically with fluid
BOX 13.1 Conventional Therapy for
Cardiogenic Shock
1. Maximize volume (RAP 10–14 mm Hg, PAWP 18–20 mm Hg)
2. Maximize oxygenation (e.g., ventilator)
3. Correct electrolyte and acid-base imbalances
4. Control rhythm (e.g., pacemaker, cardioversion)
5. Sympathomimetic amines (e.g., dobutamine, dopamine, norepinephrine)
6. Phosphodiesterase inhibitors (e.g., milrinone)
7. Vasodilators (e.g., nitroglycerin, nitroprusside)
8. Intraaortic balloon counterpulsation
PAWP, Pulmonary artery wedge pressure; RAP, right atrial pressure.
administration. Because preload is critical in patients with right ventricular shock, fluid support and avoidance of nitrates and morphine are indicated (Box 13.1).
Oxygenation and airway protection are critical. Intubation and mechanical ventilation may be required, followed by sedation, and often muscular paralysis. These interventions also improve the safety of electrical cardioversion or cardiac catheterization, if needed, and decrease oxygen demand. Positive end-expiratory pressure (PEEP) decreases preload and afterload.
Hypokalemia and hypomagnesemia predispose patients to ventricular arrhythmias and should be corrected. Because meta­bolic acidosis decreases contractile function, hyperventilation should be considered, but sodium bicarbonate should be avoided given its short half-life and the large sodium load.
Arrhythmias and atrioventricular heart block have a major influence on cardiac output. Atrial and ventricular tachyar­rhythmias should be electrically cardioverted promptly rather than treated with pharmacologic agents. Severe bradycardia due to excess vagotonia can be corrected with atropine. Temporary pacing should be initiated for high-degree heart block, preferably with a dual-chamber system. This is especially important in patients with right ventricular infarction who depend on the right atrial contribution to preload.
Aspirin and monitored unfractionated heparin should be administered to decrease the likelihood of reinfarction, ventricular mural thrombus formation, or deep venous thrombosis in the setting of low flow and hypercoagulability. Platelet P2Y
receptor
12
inhibitors (clopidogrel, prasugrel, ticagrelor) are best withheld until cardiac catheterization has determined the need for emer­gency surgery because of their prolonged action and increased risk for perioperative bleeding. Morphine sulfate decreases pain and anxiety, excessive sympathetic activity, preload, and afterload, but should only be administered in small increments. Diuretics decrease filling pressures and should be used to control volume. Beta-blockers and calcium channel blockers should be avoided because they are negative inotropic agents. An insulin infusion may be required to control hyperglycemia.
Hemodynamic Monitoring
Central hemodynamic monitoring is critical for confirming the diagnosis and guiding pharmacologic therapy (Table 13.2). Urine output needs to be monitored hourly through catheter drainage. An arterial catheter allows constant monitoring of the blood pressure. A pulmonary artery catheter should be inserted as soon
CHAPTER 13 Postmyocardial Infarction Cardiogenic Shock 143
1st line of action
2nd line of action
3r of action
https://t.me/medicina_free
Clinical signs: Shock, hypoperfusion, congestive
heart failure, acute pulmonary edema
Most likely major underlying disturbance?
Acute
pulmonary
edema
Administer
Furosemide IV 0.5 to
1.0 mg/kg*
Morphine IV 2 to 4 mg
Oxygen/intubation as needed
Nitroglycerin SL, then 10 to 20 μg/min IV if SBP greater than 100 mm Hg Dopamine 5 to 15 μg/
• kg per minute IV if SBP 70 to 100 mm Hg and signs/symptoms of shock present
Dobutamine 2 to 20 μg/ kg per minute IV if SBP 70 to 100 mm Hg and no signs/symptoms of shock
Check blood
pressure
Systolic BP
Greater than 100
mm Hg and not less
than 30 mm Hg
below baseline
Hypovolemia
Administer
• Fluids
• Blood transfusions
• Cause-specific interventions
Consider
vasopressors
Systolic BP
Greater than
100 mm Hg
Low-output
cardiogenic
Check blood
pressure
Systolic BP
70 to 100
mm Hg No signs/ symptoms
of shock
shock
Arrhythmia
Bradycardia
See Section 7.7
in the full-text
Guidelines
Systolic BP
70 to 100 mm Hg
Signs/symptoms
of shock
Tachycardia
Systolic BP
Less than
70 mm Hg
Signs/symptoms
of shock
d line
Fig. 13.2 Emergency management of complicated ST-elevation myocardial infarction. ACE,
Angiotensin-converting enzyme; BP, blood pressure; IV, intravenous; MI, myocardial infarction; SBP, systolic blood pressure; SL, sublingual. (From Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2004;110;e82.)
ACE inhibitors
• Short-acting agent such as captopril (1 to 6.25 mg)
Nitroglycerin
• 10 to 20 μg/ min IV
Further diagnostic/therapeutic considerations
(should be considered in nonhypovolemic shock)
• Pulmonary artery catheter
• Echocardiography
• Angiography for MI/ischemia
• Additional diagnostic studies
Dobutamine
• 2 to 20 μg/kg per minute IV
Diagnostic
Dopamine
• 5 to 15 μg/kg per minute IV
Intraaortic balloon pump Reperfusion/ revascularization
Norepinephrine
• 0.5 to 30 μg/ min IV
Therapeutic